Sjogrens Syndrome Measured by Ultrasound

Disease Modification in Sjogrens Syndrome Measured by Ultrasound: A Pilot Study

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03411850

Enrollment

Registered

2018-01-26

Start date

2016-05-31

Completion date

2021-12-31

Last updated

2021-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sjogren's Syndrome

Brief summary

Ultrasound study focused on salivary gland outcomes in Sjogren's subjects

Detailed description

A 32 week ultrasound study for subject diagnosed with Sjogren's Syndrome. Subjects will receive Orencia (Abatacept) as intervention therapy during this trial.

Interventions

BIOLOGICALOrencia

FDA approved biologic

OTHERPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects diagnosed with Sjogren's Syndrome

Exclusion criteria

* Subjects previously diagnosed with Sarcoidsis * Subjects with positive for Hepatitis B, Hepatitis C, HIV * Subjects diagnosed with Cancer within 5 years of screening

Design outcomes

Primary

Measure	Time frame	Description
Salivary gland changes	32 weeks	Salivary gland changes detected by ultrasound imaging with elastography

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026